You are here: Industry Insights > Ebola vaccine

News List

Janssen’s Ebola vaccine secures European regulatory approval pharmaceutical-technology
July 03, 2020
Johnson & Johnson unit Janssen Pharmaceutical Companies has received marketing authorisation from the European Commission (EC) for its vaccine regimen designed to prevent Ebola Virus Disease.
J&J to provide 200,000 Ebola vaccine regimens to Rwanda europeanpharmaceuticalreview
December 10, 2019
Johnson & Johnson has announced that it will be contributing vaccines to support the Rwandan immunisation programme to combat Ebola.
As Merck Ebola vaccine runs short in Congo, WHO looks to J&J experimental drug fiercepharma
May 12, 2019
With an Ebola outbreak in Congo outrunning vaccination efforts to control it and the supplies of Merck’s Ebola vaccine on hand, the World Health Organization has revamped its plan of attack.
Inovio announces demonstration of 100% immunogenicity of its Ebola Vaccine biospectrumasia
March 25, 2019
The Phase 1 data was published in The Journal of Infectious Diseases and further supports……
Merck & Co begins US filing of Ebola vaccine pharmaphorum
December 11, 2018
Merck & Co has begun a rolling filing in the US of its Ebola Zaire vaccine, known as V920, after the FDA said it could represent a breakthrough in treatment.
Merck’s Ebola vaccine to be used in latest Congo outbreak, with a new hurdle ahead fiercepharma
August 07, 2018
The latest Ebola outbreak in the Democratic Republic of Congo will again turn to Merck & Co’s experimental rVSV-ZEBOV that was so successful in attacking the last outbreak.
Merck to suspend filing Ebola vaccine for FDA approval until next year fiercepharma
November 23, 2017
Despite a frantic effort to rush Ebola vaccines through testing during a deadly epidemic, Merck & Co. will fall short of its goal to file its candidate for FDA approval this year, the company confirmed Tuesday. Merck is now aiming for next year.
Johnson & Johnson reports that investigational Ebola vaccine regimen induced durable immune response worldpharmanews
March 16, 2017
Johnson & Johnson announced that final Phase 1 clinical trial data published in JAMA: